Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Allogene Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -37.94%, a change of 30.81% year-over-year.
Allogene Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -62.31%, a change of 3.16% year-over-year.
Allogene Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -65.25%, a change of -4.24% year-over-year.
Allogene Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -67.24%, a change of -6.12% year-over-year.
Allogene Therapeutics, Inc. roe for fiscal 2025 was -65.25%, a change of -4.24% from fiscal 2024.
Allogene Therapeutics, Inc. roe for fiscal 2024 was -61.01%, a change of 2.88% from fiscal 2023.
Allogene Therapeutics, Inc. roe for fiscal 2023 was -63.89%, a change of -12.84% from fiscal 2022.
Allogene Therapeutics, Inc. roe for fiscal 2022 was -51.05%, a change of -31.37% from fiscal 2021.